ImmunoPrecise Antibodies (IPA) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ImmunoPrecise Antibodies Ltd. (IPA) has reported a record revenue of $24.5 million for FY 2024, a 19% year-over-year increase, driven by demand for its antibody discovery services and strategic AI investments. The company has made significant technological advances, including the launch of the LENSai API and partnerships aimed at enhancing AI-driven healthcare solutions. Despite a net loss, including a substantial impairment charge, IPA highlights robust growth prospects with an expanded laboratory capacity and advanced AI models.
For further insights into IPA stock, check out TipRanks’ Stock Analysis page.